Cancer Immunotherapy: Current Status of Treatment With Interleukin 2 and Lymphokine-Activated Killer Cells
Open Access
- 30 April 1989
- journal article
- review article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 64 (4) , 451-465
- https://doi.org/10.1016/s0025-6196(12)65736-x
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- T Lymphocytes: Ontogeny, Function, and Relevance to Clinical DisordersNew England Journal of Medicine, 1987
- Treatment of Cancer with Lymphokine-Activated Killer Cells and Interleukin-2New England Journal of Medicine, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- INTERLEUKIN-2 PRODUCES HEMODYNAMIC CHANGES SIMILAR TO SEPTIC SHOCK IN HUMANSCritical Care Medicine, 1986
- Functional characterization of T lymphocytes propagated from human lung carcinomasClinical Immunology and Immunopathology, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- THE DETAILED DISTRIBUTION OF MHC CLASS II ANTIGENS IN NORMAL HUMAN ORGANSTransplantation, 1984
- Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cellsCancer, 1984